Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET.
暂无分享,去创建一个
G. Watkins | R. Mansel | W. Jiang | J. Laterra | R. Abounader | T. Martin | J. Lane | G. Davies | C. Parr | D. Grimshaw | W. Jiang
[1] T. Nakamura,et al. Regulation of spreading and growth of colon cancer cells by hepatocyte growth factor , 1993, Clinical & Experimental Metastasis.
[2] T. Nakamura,et al. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. , 2003, Carcinogenesis.
[3] B. Davidson,et al. The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001. , 2022 .
[4] A. Giuliano,et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. , 2001, Cancer research.
[5] I. Tsarfaty,et al. Algorithms for quantitation of protein expression variation in normal versus tumor tissue as a prognostic factor in cancer: Met oncogene expression, and breast cancer as a model. , 2000, Cytometry.
[6] 谷浦 直子. Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts , 2000 .
[7] G. Bratthauer,et al. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. , 2000, Cancer research.
[8] E. Rimm,et al. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.
[9] K. Matsumoto,et al. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] I. Bièche,et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. , 1999, Analytical and quantitative cytology and histology.
[11] H. Dietz,et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. , 1999, Journal of the National Cancer Institute.
[12] M. Sasaki,et al. Mammary fibroblast-derived hepatocyte growth factor and mammogenic hormones stimulate the growth of mouse mammary epithelial cells in primary culture. , 1999, Endocrine journal.
[13] K. Matsumoto,et al. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.
[14] M. Sasaki,et al. Mammary Fibroblast‐derived Hepatocyte Growth Factor Stimulates Growth and Morphogenesis of Mouse Mammary Tumor Cells in Primary Culture , 1998, Japanese journal of cancer research : Gann.
[15] J. Horiguchi,et al. Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. , 1998, Cancer letters.
[16] E. Rimm,et al. Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.
[17] N. Funata,et al. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] M. Toi,et al. Serum hepatocyte growth factor levels in breast cancer patients with distant metastases , 1998 .
[19] K. Matsumoto,et al. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. , 1997, Cancer research.
[20] R. Mansel,et al. Regulation of the Expression of E-Cadherin on Human Cancer Cells by γ-Linolenic Acid (GLA) , 1995 .
[21] T. Imazawa,et al. Serum concentrations of hepatocyte growth factor in breast cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] R. Mansel,et al. Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). , 1995, Cancer research.
[23] K. Matsumoto,et al. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. , 1994, The Journal of biological chemistry.
[24] M. Bhargava,et al. Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor , 1994, International journal of cancer.
[25] M. Ogawa,et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. , 1994, Cancer research.
[26] T. Nakamura,et al. Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. , 1993, Cancer research.
[27] H. Kleinman,et al. Scatter factor induces blood vessel formation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[28] W. Jiang,et al. Monocyte‐conditioned media possess a novel factor which increases motility of cancer cells , 1993, International journal of cancer.
[29] L. Naldini,et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.
[30] E. Gherardi,et al. Hepatocytes and scatter factor , 1990, Nature.
[31] K. Tashiro,et al. Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.
[32] Y Iwamoto,et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.